Litcius/Paper detail

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Shengli Xia, Yuntao Zhang, Yanxia Wang, Hui Wang, Yunkai Yang, George F. Gao, Wenjie Tan, Guizhen Wu, Miao Xu, Zhiyong Lou, Weijin Huang, Wenbo Xu, Baoying Huang, Wei Wang, Wei Zhang, Na Li, Zhiqiang Xie, Xiujuan Zhu, Ling Ding, Wangyang You, Yuxiu Zhao, Jun Zhao, Lili Huang, Xuezhong Shi, Yongli Yang, Guangxue Xu, WenLing Wang, Peipei Liu, Meng Ma, YuLing Qiao, Suhua Zhao, Jingjing Chai, QinQin Li, Hui Fu, Ying Xu, Xiaotong Zheng, Wanshen Guo, Xiaoming Yang

2021The Lancet Infectious Diseases201 citationsDOIOpen Access PDF

Topics & Concepts

ImmunogenicityCoronavirus disease 2019 (COVID-19)Double blindMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyPhase (matter)Internal medicineAlternative medicineImmunologyAntibodyOutbreakPathologyPlaceboPhysicsQuantum mechanicsInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesImmune responses and vaccinations
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial | Litcius